Shares of Quanterix Corp (NASDAQ:QTRX) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $26.50.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Quanterix from a “hold” rating to a “sell” rating in a research report on Wednesday, August 22nd. Canaccord Genuity reissued a “buy” rating on shares of Quanterix in a research report on Wednesday, November 7th.
In other Quanterix news, Chairman E Kevin Hrusovsky sold 2,995 shares of the company’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $20.91, for a total transaction of $62,625.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Ernest Orticerio sold 20,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $16.82, for a total value of $336,400.00. The disclosure for this sale can be found here. Insiders have sold 43,733 shares of company stock valued at $710,080 over the last 90 days. Corporate insiders own 31.60% of the company’s stock.
NASDAQ:QTRX traded down $0.16 during trading hours on Tuesday, reaching $16.17. 83,800 shares of the company were exchanged, compared to its average volume of 99,238. The company has a market capitalization of $372.04 million and a P/E ratio of -1.95. Quanterix has a 1-year low of $13.00 and a 1-year high of $24.81. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.11 and a quick ratio of 3.76.
Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Friday, August 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.06). The company had revenue of $8.64 million for the quarter, compared to analyst estimates of $7.92 million. Quanterix had a negative return on equity of 52.34% and a negative net margin of 88.71%. On average, sell-side analysts anticipate that Quanterix will post -1.21 EPS for the current fiscal year.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Recommended Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.